Our analyses revealed statistically significant pharmacovigilance signals for several serious adverse events, including bone marrow failure, hypoplastic anemia, leukopenia, hepatic disorders and hepatitis, with particularly strong signals reported after ALB exposure. This evidence concerns the gene ALB and Hepatitis.